Key takeaways
- Right after a session, the visible change is mostly swelling, bruising, pain and numbness, not the result.
- The label allows up to 6 treatments, no less than 1 month apart; results were measured 12 weeks after the last one.
- Allergan reports composite improvement in 8% of patients after one treatment and 72% after six.
- Kybella is approved only for fat under the chin; jawline and jowl use is off-label.
- Before-and-after photos show one person's outcome, not what a reader will get.
What do you look like after one Kybella treatment?
The first after is swelling, not the end result — the trials' endpoint sat 12 weeks after the final treatment, not in the first days.
In the pooled pivotal trials, injection-site swelling occurred in 87% of Kybella patients versus 43% on placebo, bruising in 72% versus 70%, pain in 70% versus 32% and numbness in 66% versus 6%.
A photo taken in the first days after a session shows those effects, not the outcome the drug was approved to produce.
Some of those effects outlast the first week.
The label reports adverse reactions that lasted more than 30 days in more than 10% of patients: injection-site numbness in 42%, swelling in 20%, pain in 16% and hardness in 13%.
The label gives no day-by-day recovery schedule, so a chart that names the day your swelling stops isn't following the label.
Side effects lasting more than 30 days
Share of Kybella patients, reactions seen in more than 10%
Source: Kybella prescribing information
Measured change after a single session was the exception.
Allergan, the maker, reports a composite improvement — at least one grade on both the clinician's rating and the patient's own — in 8% of patients after one treatment, against 2 to 22% on placebo.
One session sits at the bottom of the maker's own ladder.
Marginal mandibular nerve injury — an uneven smile or facial-muscle weakness — occurred in 4% of Kybella patients versus under 1% on placebo; every case in the trials resolved without treatment, though recovery ranged from 1 to 298 days with a median of 44. Difficulty swallowing occurred in 2% versus under 1% on placebo and resolved without treatment with a median of 3 days (range 1 to 81). The label says people with current or prior difficulty swallowing should avoid Kybella. Contact your provider about an uneven smile or any trouble swallowing after a session.
What do Kybella results look like after a full course?
The label's ceiling is 6 treatments, no less than 1 month apart.
In the two pivotal trials, 514 people were treated with Kybella against 508 on placebo, and 59% of subjects received all six sessions.
Subjects were administered an average of 6.4 mL (64 mg) of drug at the first treatment session, and an average of 4.4 mL (44 mg) at the sixth among those who received all six treatments — with sessions no less than 1 month apart, a full course plays out over months, and the endpoint was measured 12 weeks after the last session.
Wondering about one vial?
Kybella is supplied in 2 mL single-patient-use vials holding 20 mg each; a maximum 10 mL session uses up to 5 of them, and the trial-average first session of 6.4 mL drew on a bit over 3.
We found no label or trial breakdown of results by vial count, so there is no one-vial before-and-after to show you — the amount a session uses is set within the label's dosing rules.
The endpoint the approval rests on: at 12 weeks after the final treatment, 70.0% (Trial 1) and 66.5% (Trial 2) of Kybella patients had at least a one-grade improvement on both the clinician's rating and their own, versus 18.6% and 22.2% on placebo.
The larger two-grade improvement went to 13.4% and 18.6%, against under 0.1% and 3.0% on placebo.
Allergan frames the same course as a ladder of composite improvement rates by session count:
| Number of treatments | Composite improvement (Allergan's reported rates) |
|---|---|
| 1 | 8% |
| 2 | 28% |
| 3 | 43% |
| 4 | 55% |
| 5 | 66% |
| 6 | 72% |
| Placebo | 2–22% |
Those are the manufacturer's figures from its consumer site — the shape of a course, not a promise.
Photos are a narrower guide still: they show one person's outcome, and FTC guidance treats before-and-after photos as implying the results customers can generally expect.
The measured shares above carry their own limits — they describe the trial population — but they are measured.
Kybella's label makes no permanence claim, and its trials followed patients 4, 12 and 24 weeks after their last treatment. Allergan's consumer site goes further than the label: it says destroyed fat cells "cannot store or accumulate fat" and that further treatment is not expected once you reach your goal. That is the maker's statement, not a labeled one.
Do Kybella results look different for men?
The approval is not sex-specific: Kybella is indicated for moderate to severe fullness from submental fat in adults.
The evidence base is narrow, though: two pivotal trials, in which 514 adults were treated with Kybella against 508 on placebo, produced the trial response rates on this page; the ladder of manufacturer-reported rates above comes from Allergan's consumer site.
We could not confirm men-specific response rates in the sources we checked, and no before-and-after dataset for men appears in our research.
The trial shares describe the groups as studied, not men in particular.
Whether they travel to any one man's under-chin anatomy is a question for a licensed provider.
Find Kybella for double chin providers near you
Compare Google ratings, reviews and posted prices at med spas in your city.
What about Kybella before and after on the jawline or jowls?
This is where the label draws its clearest boundary.
Kybella is approved only for the fat under the chin: the label states it is not approved for fat outside the submental region and that such use is not recommended.
Jawline and jowl uses are off-label — not on any current US label for this product — and no Kybella use outside the under-chin area is FDA-approved.
On the label
- Fat under the chin (submental) in adults
- Moderate to severe fullness
Off-label
- Jawline
- Jowls
- Any fat outside the under-chin region; the label says such use is not recommended
The label adds two expectation-setters that matter for chin photos too.
Providers are told to weigh whether excessive skin laxity or prominent platysmal bands could make reducing under-chin fat look worse rather than better, and to screen for other causes of fullness such as an enlarged thyroid or swollen lymph nodes.
Under-chin fullness, in the label's own logic, has more than one possible cause, and fat is the only one Kybella is approved to treat.
The full approval picture, session and vial numbers, cost structure and side-effect rates live in our Kybella guide.
The September 2026 label revision warns that serious adverse reactions have been reported after unapproved Kybella injections outside the submental region: blurred or reduced vision with use around the eyes, muscle or nerve injury including facial paresis and paresthesia, and nodules or masses that may not resolve.
Frequently asked questions
How many Kybella treatments until you see results?
Allergan says many patients see visible results in 2 to 4 treatments, and it reports composite improvement rates of 8% after one treatment, 28% after two, 43% after three, 55% after four, 66% after five and 72% after six, against 2 to 22% with placebo.
The label allows up to 6 treatments at least 1 month apart, and the trials measured results 12 weeks after the final session.
Is one Kybella treatment enough?
In the maker's own numbers, one session is the least likely to show the measured improvement: Allergan reports composite improvement in 8% of patients after one treatment versus 72% after six, and the trial-average first session used 6.4 mL of drug.
Whether one session suits a particular person is a judgment for a licensed provider.
What do Kybella before-and-after photos show?
One person's outcome — not a prediction.
FTC guidance treats before-and-after photos as implying the results customers can generally expect, which is exactly what a photo cannot establish.
The measured numbers in Kybella's trials varied too: 70.0% of patients in Trial 1 had at least a one-grade improvement on both the clinician's and patient ratings 12 weeks after their final treatment, while 13.4% reached a two-grade change.
Are Kybella results permanent?
The label makes no permanence claim, and its trials followed patients 4, 12 and 24 weeks after their last treatment.
Allergan's consumer site says destroyed fat cells cannot store or accumulate fat and that further treatment is not expected once you reach your goal — the maker's statement, not a labeled one.
Nothing in our research establishes what happens beyond that follow-up.
Can Kybella be used on jowls or the jawline?
Not within the label.
Kybella is approved only for moderate to severe fullness from submental fat under the chin; the label states it is not approved for fat outside that region and that such use is not recommended.
The September 2026 revision also warns of serious reactions reported after unapproved use elsewhere, including blurred or reduced vision near the eyes and muscle or nerve injury.
Sources
Every number on this page comes from one of these sources and was checked against it.
- KYBELLA- deoxycholic acid injection, solution · DailyMed, U.S. National Library of Medicine
- FAQs · mykybella.com
- 16 CFR 255.2 -- Consumer endorsements. · ecfr.gov
Medical disclaimer. MedSpaStandard is for education only and is not medical advice. Talk to a licensed provider about your own health, and check any provider's license with your state board.